Evidence map›Paper›PMID 27177655›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2016

Genotyping Single Nucleotide Polymorphisms and Copy Number Variability of the FCGRs Expressed on NK Cells.

Amy K Erbe, Wei Wang, Mikayla Gallenberger, Jacquelyn A Hank, Paul M Sondel

Open access · greenAbstract read
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. FCGR Polymorphisms Influence Response to IL2 in Metastatic Renal Cell Carcinoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2017
    Trial
  3. Article
  4. Phase I Study ofJournal of clinical oncology : official journal of the American Society of Clinical Oncology · 2025
    Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Amy K ErbeDepartment of Human Oncology, University of Wisconsin, 1111 Highland Avenue, 4136 WIMR Bldg., Madison, WI, 53705, USA. aerbe@wisc.edu.
Wei WangDepartment of Human Oncology, University of Wisconsin, 1111 Highland Avenue, 4136 WIMR Bldg., Madison, WI, 53705, USA.
Mikayla GallenbergerDepartment of Human Oncology, University of Wisconsin, 1111 Highland Avenue, 4136 WIMR Bldg., Madison, WI, 53705, USA.
Jacquelyn A HankDepartment of Human Oncology, University of Wisconsin, 1111 Highland Avenue, 4136 WIMR Bldg., Madison, WI, 53705, USA.
Paul M SondelDepartment of Human Oncology, University of Wisconsin, 1111 Highland Avenue, 4136 WIMR Bldg., Madison, WI, 53705, USA.
University of Wisconsin–Madison · US

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Enhancing Antibody-directed Innate Immunity to Improve Cancer OutcomeR35CA197078 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2015 to 2021
$6.4M
THE IMMUNOBIOLOGY OF HUMAN ANTILEUKEMIC LYMPHOCYTESR01CA032685 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 1985 to 2014
$4.3M
T-Cell Independent Antitumor Mechanisms of CD40 LigationR01CA087025 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2002 to 2012
$2.4M
Institutional Clinical and Translational Science AwardTL1TR000429 · NCATS · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2012 to 2016
$1.5M
Institutional Clinical and Translational Science Award (UW-Madison)(TL1)TL1RR025013 · NCRR · UNIVERSITY OF WISCONSIN-MADISON · PI DREZNER, MARC KENNETH · 2007 to 2011
$1.1M
The Role of KIR and FcR Genotype in the Efficacy of mAb and IL2 ImmunotherapyR01CA166105 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI SONDEL, PAUL M · 2012 to 2014
$987k
NCATS NIH HHS TL1 TR000429NCI NIH HHS P30 CA014520NCI NIH HHS R01 CA032685NCI NIH HHS R01 CA087025NCI NIH HHS R01 CA166105NCI NIH HHS R35 CA197078NCRR NIH HHS TL1 RR025013
6 · The paper itself

Abstract

Natural killer (NK) cells are one of the main effector immune cells involved in antibody-dependent cell-mediated cytotoxicity (ADCC). Upon recognition of cell-bound IgG antibodies, which occurs through Fc gamma receptors (FCGRs) expressed on the cell surface of NK cells, NK cells become activated and lyse target tumor or infected cells. The FCGRs, FCGR3A and FCGR2C, expressed on the surface of NK cells have single nucleotide polymorphisms (SNPs) that result in differential activity of NK cells. In addition to SNP genetic variation within each of these genes, the FCGRs are subject to copy number variation (CNV), which leads to variable protein expression levels on the cell surface. Studies have found that FCGR genotype for FCGR3A and FCGR2C is associated with variation in the response to immunotherapy.Due to high sequence homology within FCGR3 and FCGR2 families, there are difficulties associated with genotyping these specific receptors related to cross-amplification of non-targeted FCGRs. To improve specificity for both FCGR3A and FCGR2C, Rnase-H (RH) primers were designed to amplify specifically FCGR3A (while not co-amplifying FCGR3B) and FCGR2C (while not co-amplifying FCGR2B). In addition, fluorescently labeled locked nucleic acid (LNA) probes provide additional precision for determination of the SNPs within both FCGR3A and FCGR2C. For CNV determination, separate fluorescently labeled probes for FCGR3A, and for FCGR2C, can be used with the same RH primers for each gene. These probes can be combined in the same well with control primers/probe for a known diploid gene and used to calculate the copy number of both FCGR3A and FCGR2C. Here we provide new detailed methodology that allows for the specific amplification of these FCGRs in a single PCR reaction, allowing for genotyping of both the SNPs and CNVs using real-time PCR.

Indexed as

Polymorphism, Single NucleotideGene DosageGenotyping TechniquesHumansImmunotherapyKiller Cells, NaturalNeoplasmsPharmacogenomic VariantsReceptors, IgGSensitivity and SpecificityFCGR2C protein, humanFCGR3A protein, humanReceptors, IgGADCCCancer immunologyCNVFCGR2CFCGR3AImmunotherapyNK cellsSNP

Identifiers

PMID27177655
PMCPMC5476420
OpenAlexW2429151900

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.